Facheris Paola, Valenti Mario, Pavia Giulia, Guanziroli Elena, Narcisi Alessandra, Borroni Riccardo G, Costanzo Antonio
Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Dermatol Ther. 2020 May;33(3):e13403. doi: 10.1111/dth.13403. Epub 2020 Apr 27.
Psoriasis is a chronic inflammatory disease that affects 2% to 4% of the population; about 20% of the patients present a moderate-to-severe form. The IL-23/Th17/IL-17 molecular axis is considered crucial in the pathogenesis of psoriasis and IL-17 is fundamental in the maintenance of the immune and inflammatory alterations causing psoriasis. Expression of IL-17A, IL-17F, and IL-17C is strongly increased in psoriatic plaques. Effective therapy leads to restoration of the expression of a wide range of genes (including effector cytokines and chemokines downstream of IL-17) to near normal levels. Brodalumab is the first biologic drug targeting specifically the subunit A of the IL-17 receptor (IL-17RA) and thus inhibiting not only IL-17A but also other members of the IL-17 family. Brodalumab is very effective and safe in treating moderate-to severe psoriasis.
银屑病是一种慢性炎症性疾病，影响2%至4%的人口；约20%的患者呈现中重度形式。IL-23/Th17/IL-17分子轴被认为在银屑病发病机制中至关重要，而IL-17在维持导致银屑病的免疫和炎症改变中起关键作用。IL-17A、IL-17F和IL-17C在银屑病斑块中的表达显著增加。有效的治疗可使多种基因（包括IL-17下游的效应细胞因子和趋化因子）的表达恢复到接近正常水平。布罗达单抗是首个特异性靶向IL-17受体（IL-17RA）亚基A的生物药物，因此不仅抑制IL-17A，还抑制IL-17家族的其他成员。布罗达单抗在治疗中重度银屑病方面非常有效且安全。
